Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2018-09-12 Board/Management Inform…
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the departure of Leonard Blum, an executive vice president and general manager, effective September 26, 2018. This is a clear announcement of a change in senior management. The document length is short (2493 characters), and it does not contain financial statements or detailed financial data. Therefore, it is not an annual report, earnings release, or other financial report. The appropriate classification is Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2018-09-12 English
FORM 4 SUBMISSION
Director's Dealing
2018-09-10 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a formal communication related to a securities offering process, specifically requesting the SEC to make the registration statement effective sooner. The document is short (1203 characters) and does not contain financial data, audit information, or detailed report content. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and compliance. Therefore, it fits best under Regulatory Filings (RNS).
2018-08-17 English
FORM S-3/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-3/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is a prospectus related to the resale of shares by selling stockholders, describing the offering, risk factors, company overview, and other related information. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and offering. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2018-08-17 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-03 English
FORM 3 SUBMISSION
Director's Dealing
2018-08-03 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.